FDC Limited
FDC.BO- 1D
- +1.3%
FDC Limited in brief
FDC Limited is a listed company in the Pharmaceutical industry, based in India. Its market value was $660 M on 19 November 2026, which makes it the 11,372nd largest listed company in the world and the 777th largest in India on this site. In the year to Mar 2022 it had sales of $191 M and a net profit of $27 M, about 14 cents of profit for every dollar of sales. Its shares trade under the symbol FDC.BO (BSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
FDC Limited timeline
- 1997
- 📈Listed on National Stock Exchange of India as FDCFirst day of listing in the exchange's official list.
Events of FDC Limited from the exchanges' official lists. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
FDC Limited share price · NSE (FDC.NS)
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | 371.80 | 379.00 | 368.35 | 378.05 | +1.1% | 52,923 |
| Nov 18, 2026 | 372.00 | 378.00 | 368.50 | 373.90 | -0.5% | 65,602 |
| Nov 17, 2026 | 377.70 | 380.00 | 375.00 | 375.90 | -0.9% | 94,697 |
| Nov 16, 2026 | 369.00 | 381.00 | 369.00 | 379.40 | +2.0% | 134,326 |
| Nov 13, 2026 | 378.00 | 382.20 | 368.25 | 372.10 | -4.7% | 304,753 |
| Nov 12, 2026 | 392.10 | 396.85 | 389.00 | 390.40 | -0.7% | 364,934 |
| Nov 11, 2026 | 395.95 | 395.95 | 388.35 | 393.30 | -0.2% | 332,171 |
| Nov 9, 2026 | 395.00 | 395.45 | 389.50 | 394.20 | +1.1% | 168,140 |
| Nov 6, 2026 | 390.10 | 392.00 | 387.55 | 389.95 | -0.4% | 135,325 |
| Nov 5, 2026 | 393.50 | 395.95 | 390.00 | 391.40 | +0.1% | 337,121 |
| Nov 4, 2026 | 388.60 | 393.70 | 386.20 | 390.95 | +0.6% | 238,394 |
| Nov 3, 2026 | 382.00 | 389.00 | 380.15 | 388.60 | +2.0% | 206,752 |
| Nov 2, 2026 | 380.00 | 382.00 | 376.25 | 381.10 | +1.1% | 165,051 |
| Oct 30, 2026 | 378.50 | 383.40 | 376.10 | 377.00 | -0.0% | 246,862 |
| Oct 29, 2026 | 375.00 | 385.55 | 372.60 | 377.15 | +0.2% | 674,289 |
| Oct 28, 2026 | 385.00 | 385.95 | 366.55 | 376.55 | +6.4% | 1.9 M |
| Oct 27, 2026 | 347.70 | 356.40 | 346.75 | 353.80 | +2.1% | 195,344 |
| Oct 26, 2026 | 335.10 | 348.35 | 335.10 | 346.45 | +2.3% | 161,811 |
| Oct 23, 2026 | 342.30 | 346.60 | 330.20 | 338.70 | -0.5% | 172,360 |
| Oct 22, 2026 | 353.00 | 353.00 | 334.20 | 340.45 | +0.2% | 217,635 |
| Oct 21, 2026 | 346.00 | 348.40 | 337.00 | 339.65 | -1.1% | 70,385 |
| Oct 19, 2026 | 351.20 | 353.20 | 340.35 | 343.45 | -3.6% | 191,975 |
| Oct 16, 2026 | 352.70 | 364.90 | 343.70 | 356.25 | +1.4% | 91,489 |
| Oct 15, 2026 | 346.45 | 357.60 | 346.20 | 351.40 | +0.8% | 227,428 |
| Oct 14, 2026 | 338.00 | 350.80 | 335.85 | 348.55 | +3.0% | 105,223 |
| Oct 13, 2026 | 341.40 | 341.50 | 335.25 | 338.45 | -0.9% | 90,164 |
| Oct 12, 2026 | 331.15 | 344.00 | 330.15 | 341.40 | +3.4% | 144,826 |
| Oct 9, 2026 | 325.90 | 331.85 | 321.30 | 330.15 | +1.9% | 76,570 |
| Oct 8, 2026 | 328.30 | 330.00 | 321.40 | 324.05 | -1.4% | 113,874 |
| Oct 7, 2026 | 331.75 | 337.70 | 326.15 | 328.55 | — | 84,094 |
Prices in INR from the National Stock Exchange of India; the last 30 trading days are listed, the chart shows up to ten years. For information only; not investment advice.
FDC Limited share price statistics
Changes compare closing prices; volatility is the annualised standard deviation of daily returns. Prices are as published by the exchange, not adjusted for splits, bonus issues or dividends. For information only; not investment advice.
Market cap history
World rank over time
Rank in India: #396 (Jan 2020) · #347 (Jan 2021) · #519 (Jan 2022) · #521 (Dec 2022) · #533 (Jul 2023) · #560 (Jan 2024) · #558 (Mar 2026) · #619 (Aug 2026) · #779 (Nov 2026) · #787 (Nov 2026) · #778 (Nov 2026) · #778 (Nov 2026) · #779 (Nov 2026) · #777 (Nov 2026)
Key ratios
- P/E ratio
- 24.4×
- Price / sales
- 3.5×
- Price / book
- 2.7×
- Free cash flow yield
- —
- Net margin
- 14.1%
- Operating margin
- —
- Return on equity
- 11.0%
- Liabilities / assets
- 13.7%
Annual results
- Revenue
- $191 M
- Operating income
- —
- Net income
- $27 M
Mar-2022 ending year
Balance sheet
- Total assets
- $284 M
- Total liabilities
- $39 M
- Total equity
- $245 M
Mar-2022 ending year
Mutual funds holding FDC Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇮🇳 Nippon India Small Cap FundNippon Life India Asset Management | 4.28 M | $17 M | 3.0% | 0.21% | no change | Oct 31, 2026 |
| 🇮🇳 Tata India Pharma & Healthcare FundTata Asset Management | 1.07 M | $4 M | 0.76% | 2.7% | +7.3% | Oct 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Emerging Markets ETFSSGA Funds Management, Inc. | 404,264 | $2 M | 0.29% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Emerging Markets Core Equity 2 PortfolioDimensional Fund Advisors LP | 404,562 | $2 M | 0.29% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 The Emerging Markets Small Cap SeriesDimensional Fund Advisors LP | 169,618 | $1 M | 0.12% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Value FundDimensional Fund Advisors LP | 121,626 | $1 M | 0.09% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares MSCI India Small-Cap ETFBlackRock Fund Advisors | 88,181 | $0 M | 0.06% | 0.06% | −8.3% | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Core Equity 2 ETFDimensional Fund Advisors LP | 52,453 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 WisdomTree India Earnings FundWisdomTree Asset Management, Inc. | 43,202 | $0 M | 0.03% | <0.01% | −5.6% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Emerging Markets Small Cap ETFSSGA Funds Management, Inc. | 33,697 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis Emerging Markets Equity ETFAmerican Century ETF Trust | 32,405 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Core Equity Market ETFDimensional Fund Advisors LP | 29,786 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 29,212 | $0 M | 0.02% | <0.01% | +63% | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Social Core Equity PortfolioDimensional Fund Advisors LP | 24,242 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Value ETFDimensional Fund Advisors LP | 22,385 | $0 M | 0.02% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 17,971 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 13,171 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Emerging Markets ex China Core Equity PortfolioDimensional Fund Advisors LP | 12,343 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 11,996 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Targeted Value PortfolioDimensional Fund Advisors LP | 8,552 | $0 M | <0.01% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Sustainability Core 1 ETFDimensional Fund Advisors LP | 4,933 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 4,463 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis Emerging Markets Small Cap Equity ETFAmerican Century ETF Trust | 2,700 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis Emerging Markets Equity FundAmerican Century ETF Trust | 1,453 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis Responsible Emerging Markets Equity ETFAmerican Century ETF Trust | 1,017 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis Emerging Markets ex-China Equity ETFAmerican Century ETF Trust | 250 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets ex China Core Equity ETFDimensional Fund Advisors LP | 156 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Oct 31, 2026. The 27 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
FDA drug approvals: FDC Limited#
14 approved applications held; 2 approvals and 0 new uses in 2026.
| Approved | Drug | Kind |
|---|---|---|
| 2026-05-14 | CefiximeCefixime · ANDA218691 | Generic drug (ANDA) |
| 2026-01-08 | FluconazoleFluconazole · ANDA218692 | Generic drug (ANDA) |
| 2025-10-02 | Pilocarpine HydrochloridePilocarpine Hydrochloride · ANDA217052 | Generic drug (ANDA) |
| 2025-08-04 | Moxifloxacin HydrochlorideMoxifloxacin Hydrochloride · ANDA219475 | Generic drug (ANDA) |
| 2025-07-14 | Olopatadine HydrochlorideOlopatadine Hydrochloride · ANDA217051 | Generic drug (ANDA) |
| 2024-12-17 | CefiximeCefixime · ANDA206358 | Generic drug (ANDA) |
| 2022-01-19 | OfloxacinOfloxacin · ANDA215038 | Generic drug (ANDA) |
| 2019-09-26 | Olopatadine HydrochlorideOlopatadine Hydrochloride · ANDA209282 | Generic drug (ANDA) |
| 2019-06-13 | Dorzolamide Hydrochloride And Timolol MaleateDorzolamide Hydrochloride, Timolol Maleate · ANDA205295 | Generic drug (ANDA) |
| 2019-01-24 | Dorzolamide HydrochlorideDorzolamide Hydrochloride · ANDA205294 | Generic drug (ANDA) |
| 2016-04-22 | LatanoprostLatanoprost · ANDA202442 | Generic drug (ANDA) |
| 2009-02-25 | OfloxacinOfloxacin · ANDA078559 | Generic drug (ANDA) |
| 2008-06-30 | Ciprofloxacin HydrochlorideCiprofloxacin Hydrochloride · ANDA077568 | Generic drug (ANDA) |
| 2008-04-30 | Timolol MaleateTimolol Maleate · ANDA077259 | Generic drug (ANDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (FDC LTD), so they follow acquisitions
Discuss FDC Limited#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 27 funds hold $28 millionautomatic update · Oct 31, 2026
27 mutual funds in 2 countries hold shares of FDC Limited worth $28 million, about 4.9% of the company (funds' newest reports, up to 31 October 2026). Since their previous reports 4 funds added shares and 5 sold; on balance they sold $500,000. Share splits are not counted as trading.
How FDC Limited compares in Pharmaceutical
- Market cap$660 M · higher than 40% of 393
- Revenue$191 M · higher than 30% of 324
- Net margin14.1% · higher than 71% of 313
- P/E ratio24.4× · lower than 47% of 172
- Price / sales3.5× · lower than 37% of 219
- Price / book2.7× · lower than 41% of 207
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| FDC Limited🇮🇳 | $660 M | 24.4× | 14.1% | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Nov 19, 2026
- Annual results:
- Mar-2022 ending year
- Balance sheet:
- Mar-2022 ending year
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at FDC Limited? Verify and update this profile — free
Show FDC Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.